We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Yungjin Pharm

News List

NeuroVive and Yungjin Pharm start clinical development pharmaasia
July 13, 2017
NeuroVive and Yungjin Pharm starts clinical development in Genetic Mitochondrial disease.
NeuroVive and Yungjin Pharm Start Clinical Development in Genetic Mitochondrial Disease en-cphi.cn
June 28, 2017
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the clinical phase I study of KL1333 has started in Korea and that the first healthy volunteer
NeuroVive in-licenses a genetic mitochondrial disease clinical stage project from Yungjin Pharm pharmaasia
May 17, 2017
KL1333 is a drug intended for treatment of orphan genetic mitochondrial disorders and the in-licensed project is about to enter Phase I clinical development.
NeuroVive in partnership with Yungjin Pharm Corporation Ltd biospectrumasia
May 03, 2017
NeuroVive Pharmaceutical AB and Yungjin Pharm Corporation Ltd jointly announced that they have entered into a global licensing agreement on Yungjin Pharm's compound KL1333 for genetic mitochondrial disorders.